Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 1 2Phase 1/2 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Thoracic 1

Conditions

Prostatic Neoplasms 2Neoplasm Metastasis 1Lung Neoplasms 1Castrate-Resistant Prostate Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × OGX-011 × Clear all
NCT01630733 2026-04-15

ENSPIRIT

Achieve Life Sciences

Phase 3 Completed
664 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01188187 2016-10-14

SYNERGY

Achieve Life Sciences

Phase 3 Completed
1,022 enrolled
Genitourinary

Prostatic Neoplasms

NCT01083615 2016-10-12

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Achieve Life Sciences

Phase 3 Terminated
14 enrolled
Genitourinary

Castrate-Resistant Prostate Cancer

NCT01578655 2016-10-12

AFFINITY

Achieve Life Sciences

Phase 3 Completed
630 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡